Improving Liver Health with Probiotics: Industry Innovations

Non-invasively detecting non-alcoholic fatty liver disease (NAFLD) in a subject by measuring the amount of Lactococcus lactis and/or Dorea sp. 5-2 microbial DNA in a biological sample from the subject and comparing it to a healthy control. Elevated levels of these microbes are biomarkers indicative of NAFLD.

Compositions and methods for treating liver disorders like non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibrosis, and cirrhosis by administering a consortium of isolated and purified microbial species to improve gut function and reduce liver injury markers. The microbial compositions are formulated in ingestible forms like pills, capsules, or powders. The compositions contain specific bacterial strains like Akkermansia muciniphila, Bifidobacterium, Clostridium, Eubacterium, and Faecalibacterium that produce beneficial short chain fatty acids. Administering these microbes reduces elevated liver enzymes, indicating improved liver health.

A lactic acid bacterium called Weissella hellenica WiKim0103, isolated from Kimchi, with potential to prevent or improve fatty liver disease and inflammation. It showed an inhibitory effect on intracellular fat accumulation and reduction of fatty liver-related gene expression.

A strain of Lactobacillus reuteri, CCFM1132, that is capable of relieving hyperuricemia as well as a pharmaceutical composition containing the strain. The strain can reduce serum uric acid levels, inhibit liver xanthine oxidase activity, reduce creatinine levels, reduce serum triglycerides, reduce alkaline phosphatase activity, and increase expression of the ileum uric acid transporter ABCG2.

A composition for improving hepatic function using a green tea-derived Lactiplantibacillus plantarum strain. It can be used to prevent and treat fatty liver disease. The strain, culture, lysate or extract of the Lactiplantibacillus plantarum is administered to improve liver health.

Reducing blood alcohol concentration (BAC) levels rapidly after alcohol consumption using a combination of bifidobacterium, lactobacillus, and NAD+. The probiotic bacteria and NAD+ are given orally to a subject to reduce their BAC. The NAD+ likely speeds up alcohol metabolism via alcohol dehydrogenase enzymes, while the probiotics may have additional effects. Administering NAD+ or probiotics alone does not have the same rapid BAC reduction.

A lactic acid bacterial composition for treating or preventing jaundice that includes Bifidobacterium animalis subsp. lactis CP-9 strain and Lactobacillus salivarius subsp. salicinius AP-32 strain. Administering these strains to inhibit E.coli growth and treat/prevent jaundice.

Compositions and methods for treating cholestatic diseases, such as primary sclerosing cirrhosis, primary biliary cirrhosis, progressive familial intrahepatic cholestasis, non-alcoholic steatohepatitis, cholestasis of pregnancy, cholangitis, hepatitis, alcoholic liver disease, hepatocellular carcinoma, liver cirrhosis, cystic fibrosis, graft-vs-host disease, and obstructive cholestasis. The compositions contain specific bile acid-metabolizing bacteria that can deconjugate bile salts and modulate bile acid signaling in the gastrointestinal tract to prevent toxic bile acid buildup and liver damage.

Use of Lactobacillus helveticus ZJUIDS12 to prevent and treat alcoholic liver disease. The Lactobacillus helveticus strain can reduce liver damage from alcohol consumption. It does this by improving gut barrier function, reducing liver fat accumulation, and improving antioxidant capacity. The strain also has bile salt hydrolase activity which may help lower blood sugar levels.

Constitutively expressing an aldehyde dehydrogenase in probiotic bacteria to mitigate the toxic effects of alcohol and reduce hangovers. The probiotic bacteria are genetically modified to constitutively express aldehyde dehydrogenase. This enzyme breaks down acetaldehyde, a toxic byproduct of alcohol metabolism that causes hangover symptoms. By having the bacteria internally express the enzyme, it can break down acetaldehyde before it is absorbed into the bloodstream.

A Lactobacillus lactis strain and composition for preventing or treating non-alcoholic fatty liver disease. The strain, Lactobacillus lactis CKDB001, was isolated from milk and found to reduce fatty liver and inflammation when administered to mice with high-fat diet-induced fatty liver disease.

A lactic acid bacterial composition for treating or preventing jaundice, using specific strains of Bifidobacterium animalis subsp. lactis and Lactobacillus salivarius subsp. salicinius.

A biocontrol strain, Myroides odoratimimus, that is capable of efficiently degrading all five common types of aflatoxin toxins. The strain can be used to develop applications for preventing and treating aflatoxin contamination in food crops.

Pharmaceutical composition containing β-lapachone for prevention or treatment of cholestatic liver disease, such as primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), and inflammatory bowel disease.

Composition and diagnosis kit for diagnosing and preventing alcoholic fatty liver disease. The composition uses a Roseburia intestinalis strain that improves fatty liver symptoms. The kit measures the strain in fecal samples to diagnose disease.

Preparing an anti-hepatoma drug sanjie tablet that contains components of Typhonii Rhizoma, exocarp of Juglans mandshurica, Dictamni Cortex, and Bovis Calculus Artifactus. The preparation method involves removing toxins from these components first, and then making them into the sanjie tablet.

Lactococcus lactis subsp. lactis CCFM1018, a probiotic strain that can be used in food and medicine to help excrete the plasticizer di(2-ethylhexyl) phthalate (DEHP) from the body. DEHP is a common plasticizer that can leach from plastic products into the environment and human body, causing toxicity. The strain was found to bind and metabolize DEHP in the gut, reducing its absorption and promoting fecal excretion.

Engineered bacteria to treat liver disease like hepatic encephalopathy and NASH/NAFLD. The bacteria can be administered to the gut to reduce inflammation and ammonia levels in the gut and liver. The bacteria are genetically modified to consume excess ammonia and convert it into alternate byproducts like arginine. They also reduce inflammation by decreasing expression of genes like IL-6 and TNF-alpha in the gut and liver.

Composition and method to prevent or treat liver injury like nonalcoholic fatty liver disease (NAFLD). The composition contains a strain of Ruminococcus bacteria that can be administered as a food supplement or pharmaceutical. The Ruminococcus strain helps alleviate liver injury when given to subjects with conditions like NAFLD.

A health food and pharmaceutical composition for improving liver function using novel strains of bacteria. The strains are Lactobacillus pentosus KF8, Bacillus subtilis KF11, and Lactococcus lactis KF140. The composition contains these strains, their lysates, or culture products as active ingredients. The strains inhibit liver damage indicators like ALT and AST, reduce liver cholesterol and triglycerides, and prevent fat accumulation.